7.3.3. summary evidence recommendations treatment metastatic utuc. summary evidenceleenfortmab vedotin + pembrolizumab offers overall survival benefit compared gemcitabine-cisplatin 1st line setting.1bcisplatin-based combination chemotherapy improve median survival.2cisplatin-containing combination chemotherapy standard care advanced metastatic patients fit enough tolerate cisplatin ineligible enfortumab + pembrolizumab.1bcisplatin-containing combination chemotherapy combination nivolumab offers survival advantage compared chemotherapy alone 1st line setting.1bcarboplatin-based combination chemotherapy offers survival benefit cisplatin unfit patients.1bnon-platinum combination chemotherapy tested standard chemotherapy patients fit unfit cisplatin combination chemotherapy.4maintenance avelumab associated os advantage compared best supportive care patients disease progression 4 6 cycles gemcitabine plus either cisplatin carboplatin.1bpd-1 inhibitor pembrolizumab approved patients experienced disease progression previous platinum-based chemotherapy receive previous immune therapy based results phase iii trial.1bpd-1 inhibitor nivolumab approved patients experienced disease progression previous platinum-based chemotherapy receive previous immune therapy based results phase ii trial.2apd-1 inhibitor pembrolizumab approved patients advanced metastatic uc unfit platinum-based first-line chemotherapy based results phase ii trial use pembrolizumab restricted pd-l1 positive patients.2apd-l1 inhibitor atezolizumab approved patients advanced metastatic uc unfit platinum-based first-line chemotherapy based results phase ii trial, use atezolizumab restricted pd-l1 positive patients.2aerdafitinib associated improved overall survival platinum-refractory patients locally- advanced metastatic uc fgfr dna genomic alterations (fgfr2/3 mutations fgfr3 fusions).1benfortumab vedotin associated os benefit patients previously received platinum- containing chemotherapy experienced disease progression treatment pd-1 pd-l1 inhibitor.1bpalliative nephroureterectomy improve quality life controlling symptomatic disease.3rnu confer survival benefit highly selected patients metastatic uc e.g., response platinum-based combination chemotherapy limited metastatic burden.4 recommendationsstrength ratingoffer enfortumab vedotin combination pembrolizumab first line treatment patients advanced/metastatic disease.strongfirst-line treatment platinum-eligible patients unsuitable/ineligible forenfortumab + pembrolizumaboffer platinum combination chemotherapy platinum-eligible patients.strongoffer cisplatin based chemotherapy gemcitabine-cisplatin + nivolumab cisplatin eligible patients.weakoffer cisplatin-based chemotherapy gemcitabine/cisplatin hd-mvac cisplatin- eligible patients.strongoffer gemcitabine/carboplatin chemotherapy cisplatin-ineligible patients.strongoffer maintenance avelumab patients disease progression 4 6 cycles platinum-based combination chemotherapy.strongfirst-line treatment patients ineligible combination therapyoffer checkpoint inhibitors pembrolizumab atezolizumab patients pd-l1 positive tumours.weaklater lines treatmentoffer platinum based combination chemotherapy second line treatment choice received first line setting.strongoffer checkpoint inhibitor (pembrolizumab) patients disease progression platinum-based combination chemotherapy metastatic disease receive maintenance avelumab.strongoffer enfortumab vedotin patients previously treated platinum-containing chemotherapy disease progression treatment pd-1 pd-l1 inhibitor.strongtest utuc patients fgfr alterations (fgfr2/3 mutations fgfr3 fusions) prior erdafitinib treatment.strongoffer erdafitinib alternative subsequent-line therapy patients:previously treated platinum-containing chemotherapy;who disease progression treatment pd-1 pd-l1 inhibitor;who harbour fgfr dna genomic alterations (fgfr2/3 mutations fgfr3 fusions).strongonly offer vinflunine patients metastatic disease second-line treatment immunotherapy combination chemotherapy feasible. alternatively, offer vinflunine third- subsequent-line treatment.strongoffer nephroureterectomy palliative treatment symptomatic patients resectable locally-advanced tumours.weak dna = deoxyribonucleic acid; fgfr = fibroblast growth factor receptors; hd-mvac = high-dose intensity methotrexate, vinblastine, adriamycin plus cisplatin; pd-l1 = programmed death ligand 1.